Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Lactic acid bacteria (LAB) have a long history of safe exploitation by humans, being used for centuries in food production and preservation and as probiotic agents to promote human health. Interestingly, some species of these Gram-positive bacteria, which are generally recognized as safe organisms by the US Food and Drug Administration (FDA), are able to survive through the gastrointestinal tract (GIT), being capable to reach and colonize the intestine, where they play an important role. Besides, during the last decades, an important effort has been done for the development of tools to use LAB as microbial cell factories for the production of proteins of interest. Given the need to develop effective strategies for the delivery of prophylactic and therapeutic molecules, LAB have appeared as an appealing option for the oral, intranasal and vaginal delivery of such molecules. So far, these genetically modified organisms have been successfully used as vehicles for delivering functional proteins to mucosal tissues in the treatment of many different pathologies including GIT related pathologies, diabetes, cancer and viral infections, among others. Interestingly, the administration of such microorganisms would suppose a significant decrease in the production cost of the treatments agents since being live organisms, such vectors would be able to autonomously amplify and produce and deliver the protein of interest. In this context, this review aims to provide an overview of the use of LAB engineered as a promising alternative as well as a safety delivery platform of recombinant proteins for the treatment of a wide range of diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preservation and Fermentation: Past, Present and Future
Paul Ross, R., Morgan, S., & Hill, C. (2002) · International Journal of Food Microbiology · doi:10.1016/s0168-1605(02)00174-5 · Cited by 942
Doron, S., & Snydman, D. R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ085 · Cited by 942
Probiotics and the gut microbiota in intestinal health and disease
Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.117 · Cited by 907
A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s Disease
Braat, H., Rottiers, P., Hommes, D. W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S. J. H., Neirynck, S., Peppelenbosch, M. P., & Steidler, L. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.028 · Cited by 786 · cited 11×
“Expression of IL-10, which is a regulatory cytokine, would decrease inflammation thanks to its antinflammatory activity [26], while the use of enzymes such as catalase would act on the inflammatory response derived from the presence of reactive oxygen species (ROS) [24, 25].”
BackgroundMethodInfluentialA systematic review of the safety of probiotics
Didari, T., Solki, S., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.872627 · Cited by 367 · cited 3×
“Besides, it should be noted that some adverse effects of LAB have been reported [104] [105] [106] .”
BackgroundAntiobesity and lipid-lowering effects of Bifidobacterium spp. in high fat diet-induced obese rats
An, H. M., Park, S. Y., Lee, D. K., Kim, J. R., Cha, M. K., Lee, S. W., Lim, H. T., Kim, K. J., & Ha, N. J. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-116 · Cited by 320
Vandenbroucke, K., Hans, W., Van Huysse, J., Neirynck, S., Demetter, P., Remaut, E., Rottiers, P., & Steidler, L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.05.020 · Cited by 277 · cited 3×
“Some strategies have been proposed using proteins such as low-calcium V antigen (LcrV) [21], anti-TNFα nanobodies [22], trefoil factors (TFF) [23], catalase [24, 25] and IL-10 [26] using L. lactis as microbial delivery vector (Table 1).”
BackgroundMethodFood-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis
Motta, J.-P., Bermúdez-Humarán, L. G., Deraison, C., Martin, L., Rolland, C., Rousset, P., Boue, J., Dietrich, G., Chapman, K., Kharrat, P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004212 · Cited by 257 · cited 2×
“Besides, elafin, an endogenous protease inhibitor, has also been orally administered using L. lactis and L. casei as delivery vectors, observing a restoration of colon homeostasis in mice [11, 36, 37] .”
BackgroundCarroll, I. M., Andrus, J. M., Bruno-Bárcena, J. M., Klaenhammer, T. R., Hassan, H. M., & Threadgill, D. S. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00132.2007 · Cited by 208 · cited 1×
“Lactobacillus gasseri/ Lactobacillus casei IDB Superoxide Dis‐ mutase (SOD) pSodA pILKSsodA sodA native promoter – [39, 40]”
BackgroundGoldin, B. R., Gualtieri, L. J., & Moore, R. P. (1996) · Nutrition and Cancer · doi:10.1080/01635589609514442 · Cited by 186 · cited 1×
“Some examples of the strains used with this purpose are Bifidobacterium lactis [49] , L. casei strain Shirota [50] , B. longum BB536 [51] , Lactobacillus acidophilus Delvo Pro LA-1 [52] , Lactobacillus rhamnosus GG [53] or Propionibacterium freudenreichii [54] but many others rendered similar results, showing a signif…”
Result
Cited by
Marco, M. L., Sanders, M. E., Gänzle, M., Arrieta, M. C., Cotter, P. D., De Vuyst, L., Hill, C., Holzapfel, W., Lebeer, S., Merenstein, D., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00390-5 · Cited by 937
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
“diseases, cancer, and metabolic diseases (Cano-Garrido et al., 2015; Singh et al., 2017).”
Engineering Microbial Living Therapeutics: The Synthetic Biology Toolbox
Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., de Jesus, V. N., Cozetto, D. A., Tuma, R. B., Gracindo, A., Cesar, M. B., Freire, P. J. C., da Costa, A. F. M., et al. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.005 · Cited by 189
Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
Wegmann, U., Carvalho, A. L., Stocks, M., & Carding, S. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-02591-6 · Cited by 53
Metadata
- Authors
- Cano-Garrido, O., Seras-Franzoso, J., & Garcia-Fruitós, E.
- Venue
- Microbial Cell Factories
- Published
- 2015-09-16
- Volume
- 14
- Issue
- 1
- Pages
- 137-137
- ISSN
- 1475-2859 (ISSN-L)
- OpenAlex
- W1914752606
- Cited by
- 147
- References
- 11
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. https://app.cochat.ai/papers/10.1186/s12934-015-0313-6
- The paper
- Cano-Garrido, O., Seras-Franzoso, J., & Garcia-Fruitós, E. (2015). Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microbial Cell Factories. https://doi.org/10.1186/s12934-015-0313-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.